

Coding Options for Administration of CAR-T Updated as of October 1, 2021

Coding Options for Reporting Administration of Autologous CAR-T	Inpatient Claim - Facility Reporting and Payment Implications ¹			Outpatient Claim - Facility Reporting and Payment Implications					Physician Claim - Professional Services Reporting and Payment Implications			
	ICD-10-PCS Codes	Revenue Codes for Charges ²	Description	CPT/HCPCS Codes	Revenue Codes for Charges ²	Description	Medicare Payment Implications	Commercial Payment Implications	CPT/HCPCS Codes	Description	Medicare Considerations and Payment Implications	Commercial Payment Implications
	XW033C7 or XW043C7 XW033J7 or XW043J7 XW033H7 or XW043H7 XW033M7 or XW043M7 XW033N7 or XW043N7 XW033K7 or XW043K7 XW033A7 or XW043A7	0874	Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein (or Central) Percutaneous Approach, New Technology Group 7 (Used for any autologous CAR-T product, such as those currently under trial, where there is no product-specific ICD-10-PCS code to describe the product) Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein (or Central), Percutaneous Approach, New Technology Group 7 Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein (or Central), Percutaneous Approach, New Technology Group 7 Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein (or Central), Percutaneous Approach, New Technology Group 7 Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein (or Central), Percutaneous Approach, New Technology Group 7 Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein (or Central), Percutaneous Approach, New Technology Group 7 Introduction of Ciltacabtagene Autoleucel into Peripheral Vein (or Central), Percutaneous Approach, New Technology Group 7	0540T	0874	Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous	OPPS Indicator = "S" ("significant procedure") Placed in APC 5694 While assigned a payment rate by Medicare, providers should still reach out to their Medicare Administrative Contractors (MACs) to confirm the code will be allowed/recognized, as the MAC may have a local policy that limits usage or applies edits to Category III codes.	Providers should contact their commercial payers and share this information to ensure the code is accepted as part of their contract.	0540T	Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous	Recognized as a carrier-priced service as designated by status code "C" in the MPFS. Category III codes are manually priced by the MAC based on a written explanation of the service and usually a code provided by the clinician as a reasonable proxy to cross-walk to for payment purposes; CPT code 38241 is a possible cross-walk code choice if the clinician feels CAR-T administration requires similar resource utilization as autologous hematopoietic progenitor cell (HPC) transplantation; if not, then a different code/service will need to be provided to the MAC Despite being deemed carrier priced, providers will need to reach out to their MACs to confirm the code will be allowed/recognized, as the MAC may have a local policy that that limits usage or applies edits to Category III codes.	Providers should contact their commercial payers and share this information to ensure the code is accepted as part of their contract
XW033G7 or XW043G7	0874	Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein (or Central), Percutaneous Approach, New Technology Group 7 (Used to describe the administration of any allogeneic CAR-T product)	Recommended: 38999 ³	0874	Unlisted procedure, hemic or lymphatic system	Medicare typically assigns unlisted codes to the lowest paying APC in the applicable APC range.	All payers and providers must follow HIPAA code sets and guidelines. AMA/CPT codes and guidelines are part of HIPAA transaction code sets. Because 38999 is an unlisted CPT code, payers may request additional information. Providers should refer to their contracts.	Recommended: 38999 ³	Unlisted procedure, hemic or lymphatic system	Medicare typically assigns unlisted codes to the lowest paying APC in the applicable APC range.	All payers and providers must follow HIPAA code sets and guidelines. AMA/CPT codes and guidelines are part of HIPAA transaction code sets. Because 38999 is an unlisted CPT code, payers may request additional information. Providers should refer to their contracts.	

¹ For Medicare, MS-DRG 018 is assigned for inpatient CAR-T administration based on reporting a CAR-T administration ICD-10-PCS procedure code. A payment adjustment will be applied to claims that group to MS-DRG 018 and include ICD-10-CM diagnosis code Z00.6 or when there is expanded access use of immunotherapy. However, when the provider incurs a cost for the CAR T-cell therapy product and the case involves a clinical trial of a different product, the payment adjustment will not be applied, and the provider will receive the full MS-DRG 018 payment. Providers will have to notify their MACs of these situations. To notify the MAC of a case where there was expanded access of CAR T-cell therapy products, the provider may enter a Billing Note NTE02 "Expand Acc Use" on the electronic claim 837i or a remark "Expand Acc Use" on a paper claim. To notify the MAC of a case where the CAR T-cell therapy product is purchased in the usual manner, but the case involves a clinical trial of a different product (and ICD-10-CM diagnosis code Z00.6 is on the claim), the provider may enter a Billing Note NTE02 "Diff Prod Clin Trial" on the electronic claim 837i or a remark "Diff Prod Clin Trial" on a paper claim. Providers should carefully review the guidance released by CMS in Transmittal R10360CP, effective Oct 5, 2020. This can be found at: <https://www.cms.gov/files/document/r10360cp.pdf>. For commercial payer or State Medicaid inpatient payment, providers need to check their contracts or agreements.

² Hospital should report a procedure charge for the cell administration whether inpatient at the bedside or outpatient

Note 1: Do not report unlisted code 38999 for cell collection or cell processing services for autologous CAR-T services (for allogeneic, see ³ below) now that more specific codes are available - see the National Correct Coding Initiative (NCCI) edit manual

Note 2: New revenue codes have been in place since April 1, 2019 for reporting cell collection and cell processing services; see the National Uniform Billing Committee (NUBC) manual: <http://www.nubc.org/subscribersonly/PDFs/Cell%20Therapy%20Changes%20August%202018.pdf>; all providers and payers have to use the new codes per the HIPAA transaction code set regulation.

³ Since there is no specific CPT code for allogeneic CAR-T administration, per AMA/CPT guidance, do not select a CPT code that merely approximates the service provided. If there are no codes that accurately identify the service being provided, report the service using the approximate unlisted procedure or service code. See Introduction section, "Instructions for the Use of the CPT Codebook", in American Medical Association (AMA), CPT Professional Edition 2021 code book, Chicago (IL): AMA, 2020.

DISCLAIMER: This information was obtained from third-party sources and is subject to change at any time without notice, including as a result of changes in coding, reimbursement, laws, regulations, rules, and policies. Content is informational only, and does not cover all situations or all payers' rules or policies. This document represents no promise or guarantee by ASTCT regarding coverage or reimbursement. The ultimate responsibility for coding and claims submissions lies with the physician, clinician, hospital, and/or other facility. Providers should consult their payers and check bulletins, manuals, program memoranda, and guidelines to ensure compliance with requirements.